In one paragraphArticle in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
9 authors at 3 institutions in 2 countries.
Sandra Arroyo-UreaInstitute for Biocomputation and Physics of Complex Systems (BIFI) and Laboratorio de Microscopías Avanzadas (LMA), University of Zaragoza, 50018, Zaragoza, Spain.
Antonina L NazarovaDepartment of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA 90089.
Ángela Carrión-AntolíInstitute for Biocomputation and Physics of Complex Systems (BIFI) and Laboratorio de Microscopías Avanzadas (LMA), University of Zaragoza, 50018, Zaragoza, Spain.
Alessandro BonifaziMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States.ORCID 0000-0002-7306-0114 Francisco O BattitiMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States.
Jordy Homing LamDepartment of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA 90089.ORCID 0000-0002-5496-6228 Amy Hauck NewmanMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States.ORCID 0000-0002-4812-9474 Vsevolod KatritchDepartment of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA 90089.ORCID 0000-0003-3883-4505 Javier García-NafríaInstitute for Biocomputation and Physics of Complex Systems (BIFI) and Laboratorio de Microscopías Avanzadas (LMA), University of Zaragoza, 50018, Zaragoza, Spain.ORCID 0000-0002-4254-3148 University of Southern California · USUniversidad de Zaragoza · ESNational Institutes of Health · US
Funding
NOVEL DOPAMINE D3 RECEPTOR LIGANDSZ01DA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 1999 to 2008
$1.8MEfficient synthon-based modular screening of Giga-to-Terra-scale virtual librariesR01GM147537 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KATRITCH, VSEVOLOD · 2022 to 2024
$1.2MIntramural NIH HHS Z01 DA000424NIGMS NIH HHS R01 GM147537
6 · The paper itselfAbstract
Although aminergic GPCRs are the target for ~25% of approved drugs, developing subtype selective drugs is a major challenge due to the high sequence conservation at their orthosteric binding site. Bitopic ligands are covalently joined orthosteric and allosteric pharmacophores with the potential to boost receptor selectivity, driven by the binding of the secondary pharmacophore to non-conserved regions of the receptor. Although bitopic ligands have great potential to improve current medications by reducing off-target side effects, the lack of structural information on their binding mode impedes rational design. Here we determine the cryo-EM structure of the hD
Indexed as
bitopic drugscryo-EMdopamine D3 receptordrug selectivityGPCRG protein-coupled receptors
Identifiers
PMID38196573
PMCPMC10775388
OpenAlexW4389914678
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390